Published in final edited form as:

Acc Chem Res. 2018 April 17; 51(4): 940–949. doi:10.1021/acs.accounts.8b00036.

Protein-Protein Interactions (PPIs) in the Molecular Chaperone Network

Rebecca Freilich, Taylor Arhar, Jennifer L. Abrams, and Jason E. Gestwicki

Department of Pharmaceutical Chemistry and The Institute for Neurodegenerative Disease

University of California - San Francisco, San Francisco, CA 94158

Graphical Abstract

Conspectus.

Molecular chaperones play a central role in protein homeostasis (aka proteostasis) by balancing protein folding, quality control and turnover. To perform these diverse tasks, chaperones need the malleability to bind nearly any “client” protein and the fidelity to detect when it is misfolded. Remarkably, these activities are carried out by only ~180 dedicated chaperones in humans. How do a relatively small number of chaperones maintain cellular and organismal proteostasis for an entire proteome? Further, once a chaperone binds a client, how does it “decide” what to do with it? One clue comes from observations that individual chaperones engage in protein-protein interactions (PPIs) – both with each other and with their clients. These physical links coordinate multiple chaperones into organized, functional complexes and facilitate the “hand off” of clients between them. PPIs also link chaperones and their clients to other cellular pathways, such as those that mediate trafficking (*e.g.*, cytoskeleton) and degradation (*e.g.*, proteasome). The PPIs of the chaperone network have a wide range of affinity values (nanomolar to micromolar) and involve many distinct types of domain modules, such as J domains, zinc fingers and tetratricopeptide repeats. Many of these motifs have the same binding surfaces on shared partners, such that members of one chaperone class often compete for the same interactions. Somehow, this collection of PPIs draws together chaperone families and creates multi-protein subnetworks that are able to

Correspondence to: Jason E. Gestwicki.

Correspondence: Jason E. Gestwicki, Ph.D., UCSF, 675 Nelson Rising Lane, San Francisco, CA 94158, Tel (415) 502 7121, Jason.gestwicki@ucsf.edu.

make the “decisions” of protein quality control. The key to understanding chaperone-mediated proteostasis might be to understand how PPIs are regulated.

This Account will discuss the efforts of our group and others to map, measure and chemically perturb the PPIs within the molecular chaperone network. Structural biology methods, including X-ray crystallography, NMR and electron microscopy, have all played important roles in visualizing the chaperone PPIs. Guided by these efforts and –omics approaches to measuring PPIs, new advances in high throughput chemical screening, specially designed to account for the challenges of this system, have emerged. Indeed, chemical biology has played a particularly important role in this effort, as molecules that either promote or inhibit specific PPIs have proven to be invaluable research probes in cells and animals. In addition, these molecules have provided leads for the potential treatment of protein misfolding diseases. One of the major products of this research field has been the identification of putative PPI drug targets within the chaperone network, which might be used to change chaperone “decisions” and re-balance proteostasis.

1 Introduction to the Chaperone Network.

The largest class of molecular chaperones is the heat shock proteins¹, which are named for their apparent molecular mass (in kDa): Hsp90, Hsp70, Hsp60, Hsp40 and the small heat shock proteins (sHsps). The heat shock proteins are abundant and conserved through all kingdoms of life, suggesting that they are an ancient way of protecting proteomes. In their simplest form, the “job” of the chaperones is to bind clients and protect them from aggregation. Some chaperones, such as Hsp70, accomplish this task by interacting reversibly with exposed hydrophobic regions, limiting aberrant (*i.e.*, non-native) contacts. Beyond this simple anti-aggregation activity, groups of chaperones are able to carry out more sophisticated functions, such as folding or dis-aggregating proteins. These activities are typically powered by ATP hydrolysis, and they often require the coordinated efforts of multiple chaperones and cochaperones from different categories (*e.g.*, Hsp70s and Hsp40s) working together.

In this review, we focus on the PPIs between chaperones. A map of the PPIs between chaperones shows that all of the major categories are physically linked to each other, either directly or through intermediary, scaffolding factors (Figure 1). For example, PPIs link the sHsps, such as Hsp27 and Hsp22, to Hsp70 and Hsp90 through the scaffolding co-chaperones BAG3 and HOP/Sti1. Other chains of PPIs link classes of chaperones, such as prefoldin and TriC, to Hsp70 and Hsp40s. In prokaryotes and yeast, PPIs (dotted lines, Figure 1) provide additional connectivity. However, it is important to note that these PPIs are not all the same. They occur with a wide range of affinity values, from strong (*e.g.* Hsp70-BAG1, $\sim 0.012 \mu\text{M}^2$; Hsp70-CHIP, $\sim 0.5 \mu\text{M}^3$) to very weak (Hsp90-p23, $\sim 1 \mu\text{M}^4$; Hsp70-Hsp40, $\sim 110 \mu\text{M}^5$), and they involve contact surfaces that are either small or quite large (Hsp70-BAG1, $>4000 \text{ \AA}^2$)⁶.

Our group, and many others, think that this PPI network architecture is critical to the ultimate functions of the chaperones⁷. It is known that some clients undergo “handoff” from one chaperone to another through these conduits, perhaps minimizing their exposure to

bystanders. For example, steroid hormone receptors (SHRs) are shuttled between Hsp70 and Hsp90 through the action of HOP⁸ (see Figure 1). In other examples, replacing one chaperone for another has been shown to “switch” the overall function. For example, while Hsp70 and HOP are linked to folding of SHRs, a complex of Hsp70 and CHIP is linked to their degradation⁸. Together, these observations give the impression of a dynamic, interconnected web of chaperones that coordinate their functions and share molecular information to maintain proteostasis. Indeed, this concept has been mathematically modelled in the prokaryotic⁹ and limited parts of the eukaryotic system¹⁰, using inputs such as the affinity constants, protein concentrations, turnover and changes in nucleotide. This computational approach can even robustly replicate the complex folding characteristics seen in cells¹¹, showing the depth of knowledge in this system.

Because PPIs are so critical in dictating chaperone functionality, chemical probes that target particular interactions are extremely useful tools for understanding network function. Furthermore, it is possible that small molecules of this type could be more selective than compounds acting at conserved, active sites. The problem is that PPIs are challenging drug targets, as recently reviewed¹². One needs high throughput and, ideally, the ability to monitor physical interactions. Chaperone networks have additional complication because many of the interactions are weak, limiting the types of discovery platforms that can be used. Towards that goal, our lab and others have used both direct and indirect high throughput screening (HTS) approach to identify small molecules that modulate chaperone PPIs. For example, we identified inhibitors of the Hsp70-BAG3 interaction using flow cytometry and isoelectric focusing capillary electrophoresis (ICE) to directly detect disruption of PPIs^{13,14}. Another approach is screening against the enzymatic activity of a reconstituted multi-protein complex (RMPC), which we have used to identify inhibitors of Hsp70/J-protein/NEF interactions^{15,16}. Another emerging method is differential scanning fluorimetry (DSF), which we used to identify molecules that stabilize native dimers of the small HSPs¹⁷.

In the next sections, we briefly review the major classes of chaperones. We do not intend this discussion to be inclusive, because many reviews have covered the topics of chaperones¹, the stress response¹⁸ and their roles in disease¹⁹. Rather, we focus here on the PPIs – the dynamic “glue” on which the chaperone network is assembled – and we highlight the important roles that small molecules have played.

2. Heat shock protein 70 (Hsp70).

Hsp70 is a good starting-point for a discussion of chaperone PPIs, as it makes a number of well-characterized contacts (Figure 2). Hsp70 has been shown to be critical for a wide range of activities, including protein folding, chaperone-mediated autophagy (CMA) and endocytosis. Because of its central role in delivering clients to so many different pathways, Hsp70 is often considered the “triage” chaperone. All members of the Hsp70 family are composed of a nucleotide-binding (NBD) domain, which has ATPase activity, and a substrate-binding domain (SBD) that makes contact with the client. In the ATP-bound state, Hsp70 binds weakly to its clients, while nucleotide hydrolysis slows the off-rate and increases affinity^{20,21}. Through this deceptively simple system of ATP-driven “catch-and-

release”, Hsp70 plays roles in folding, turnover, the assembly/disassembly of protein complexes, protein translocation and trafficking.

How can one factor be involved in so many disparate processes? By design, Hsp70 binds to clients weakly (typically micromolar) and with little sequence selectivity, making it a promiscuous chaperone. It is thought that PPIs with co-chaperones are the key to providing specificity and functionality^{7,21}. For example, Hsp40s (also called J proteins) are adapters of the Hsp70 system that recruit it to specific clients; for example, auxilin recruits Hsp70 specifically to clathrin²². More broadly, Hsp70 binds to three major categories of co-chaperones: Hsp40s, nucleotide exchange factors (NEFs) and tetratricopeptide repeat (TPR) proteins (Figure 2). There are ~50 Hsp40/J protein genes in humans, and dozens of NEFs and TPR proteins. Moreover, each of the individual co-chaperones brings its own functionality into the system, as outlined in the sections below. Thus, with the large number of Hsp70s and co-chaperones in the human genome, thousands of possible Hsp70-client-Hsp40-NEF-TPR combinations are possible.

Hsp40s/J Proteins.

The Hsp40/J proteins are a group of co-chaperones that contain a conserved J-domain²³. J-domains make contact with Hsp70s via electrostatic interactions between the positively charged helix II of the J-domain and negatively charged region composed of lobes IA and IIA of the NBD, the inter-domain linker, and the β sandwich domain in the SBD (Figure 2B)^{24–26} (Kityk et al Mol Cell 2018). This PPI surface is strikingly “spread out” and polar, as well as weak (K_D estimated ~ 10 μ M), placing it in a category of PPIs that is notoriously difficult to inhibit¹². Despite this challenge, a class of dihydropyrimidines takes advantage of a relatively deep groove between the IA and IIA lobes of Hsp70 to either disrupt or promote the J-domain contact⁵. Work by our group and others have advanced these molecules as chemical probes for a number of disease systems^{27,28}.

The PPI between Hsp70 and its Hsp40s/J proteins has a number of important consequences. Firstly, it stimulates Hsp70’s ATPase activity²⁵. The intrinsic rate of nucleotide turnover is slow, so this stimulatory activity is important for converting Hsp70 to the tight-binding conformer. Second, the Hsp40s/J proteins often include second domains that bind directly to clients and recruit them to the Hsp70 system²³. In this role, some Hsp40s/J proteins are highly specialized; for example, auxillin (DnaJC6) recruits Hsp70 specifically to clathrin-coated vesicles²². However, other Hsp40s/J proteins are relatively promiscuous, recognizing a wider range of proteins²⁹. Some of the Hsp40s/J proteins also have additional domains that link them to other chaperones within the network; for example, DnaJC7 also binds Hsp90³. Finally, many of these co-chaperones engage in PPIs with themselves as part of oligomers, which might be important for certain functions, such as disaggregation³⁰. Together, these diverse PPIs make Hsp40s/J proteins central adapters of the network.

Nucleotide Exchange Factors (NEFs).

NEFs are co-chaperones that release ADP and clients from Hsp70³¹. There are four distinct structural categories of human NEFs, each of which uses a different binding mode. Although these categories of NEFs use different PPI interfaces, they all act to stabilize the “open”

form of Hsp70's NBD, accelerating release of ADP and client. The prokaryotic GrpE and its human ortholog, GrpEL1 or HMGE, accomplish this goal using a β -domain to interact with lobes IB and IIB³². Members of the BAG family use a 3-helix bundle to make hydrophobic and electrostatic contacts with a similar region³³. Work from our group has indicated that some BAG family members, such as BAG1 and BAG3, make an additional, non-canonical interaction with Hsp70's SBD which is essential for release of clients². Recent studies have confirmed this non-canonical interaction in other NEF systems too, such as Sil1³⁴, Fes1 and HspBP1³⁵. Members of the Hsp110/Grp170 family use a completely different approach, making extensive contacts with lobe IIB of the NBD³⁶. Finally, HspBP1/Sil1 family members use four armadillo-repeats to bind to lobe IIB, destabilizing the NBD³⁷. The PPIs between Hsp70 and NEFs are relatively strong (K_D values in the low to mid nanomolar range), but the interaction surfaces have complex topology. Despite the complexity of these PPIs, inhibitors of Hsp70-NEF have been described. The best studied are the MKT-077 family of small molecules, which bind to a conserved allosteric site on Hsp70³⁸ and stabilize the ADP-bound state³⁹. As discussed below, these molecules have been powerful probes for understanding the roles of Hsp70 and the NEFs in proteostasis.

In addition to their activity on Hsp70, some NEFs are multi-domain adapters that bind to proteins in other pathways. For example, Hsp110 binds to misfolded proteins, preferring aromatic residues and potentially expanding Hsp70's client pool⁴⁰. Thus, NEFs are not only important for nucleotide cycling, but they also seem to be key in coordinating handoff to other chaperones and pathways.

Tetratricopeptide Repeat (TPR) Proteins.

Tetratricopeptide repeat domains are defined by three or more tandem TPR motifs that encode amphipathic helices^{41,42}. There are hundreds of TPR domain-containing proteins expressed in humans, but a subset contains a conserved lysine and two asparagines, which is termed a "carboxylate clamp". These residues make hydrogen bonds with the extreme C-termini of the cytosolic Hsp70s and Hsp90s, in a shared motif defined by the amino acids EEVDCOOH⁴³. While most of the binding energy for this interaction seems to come from the interaction of the EEVD with the carboxylate clamp⁴⁴, residues preceding the EEVD sequence have been shown to contribute to specificity; for example, FKBP51 and FKBP52 prefer Hsp90's MEEVD, while CHIP and DnaJC7 prefer Hsp70's IEEVD³. These differences provide a hierarchy of K_d values from ~10 μ M to less than 1 μ M. Because of the polar nature of the EEVD-TPR contact, few molecules have been reported to inhibit this PPI.

The defining feature of the TPR containing co-chaperones is that they bring specific enzymatic functions into the chaperone complexes⁴⁵. For example, CHIP is an E3 ubiquitin ligase that acts on chaperone-bound clients, while PP5 is a protein phosphatase and FKBP51/52 are peptidyl prolyl isomerases. Thus, the identity of the bound TPR co-chaperone often seems to determine what ultimately happens to the chaperone's client.

Putting It All Together.

How do Hsp70 and its co-chaperones come together to make “decisions” about client fate? Our group has taken a chemical biology approach to this question, using small molecules to perturb individual PPIs and asking how client fate is impacted in cells and tissues. Recent reviews have described these chemical probes and their mechanisms in more detail^{46,47}. Here, we focus on analogs of MKT-077, such as JG-48, which have been shown to inhibit the PPI between Hsp70-NEF³⁹. Because NEFs normally promote the release of clients, JG-48 significantly stabilizes the Hsp70-client complex, as shown *in vitro* and in cells. What is the consequence of this? Strikingly, a number of groups have found that JG-48 and its analogs promote the turnover of multiple Hsp70 clients, including tau⁴⁸, polyglutamine proteins⁴⁹, Dengue viral proteins⁵⁰ and oncoproteins⁵¹. Thus, it seems that Hsp70 and its NEFs may normally monitor the dwell time of clients and promote their degradation if they remain “too long”⁵². Chemical inhibitors promote turnover by limiting the ability of NEFs to release client, which could be a favorable activity in models of neurodegeneration and cancer.

Other Hsp70 Interactions in Prokaryotes.

As mentioned above, Hsp70 cochaperones, such as BAG3 and HOP, play an important “adapter” role in eukaryotes. However, many of these adaptors do not exist in prokaryotes, and there is some evidence that, in those systems, the major prokaryotic chaperones coordinate directly in their absence. For example, prokaryotic DnaK/Hsp70 directly interacts with prokaryotic Hsp90 (termed HtpG) and ClpB^{53,54}. Some of these direct interactions are also present in yeast orthologs, such as Hsp70 binding to Hsp104⁵⁵. These examples suggest that PPIs have always been used to build chaperone networks and that evolution has only further elaborated that scheme.

2. Hsp90.

Hsp90 is another major “hub” of the chaperone network, interacting with a large number of co-chaperones and clients⁵⁶. Based on pioneering work in SHRs, Hsp90 is thought to recognize clients in later stages of folding, functioning in their stability and activation⁵⁷. Hsp90 has three domains: an amino-terminal domain (NTD) that is responsible for binding to ATP⁵⁸, a middle domain (MD) that is required for ATPase activity⁵⁹, a carboxy-terminal domain (CTD) that is responsible for homodimerization⁶⁰ and terminates in the MEEVD motif that binds TPR co-chaperones⁴². The Hsp90 homodimer undergoes dramatic conformational rearrangements over the course of its ATPase cycle, in which binding of ATP promotes a closed state where the NTDs dimerize, allowing for ATP hydrolysis. A number of inhibitors, most notably geldanamycin and radicicol, have been found to compete for binding with ATP, thus inhibiting Hsp90 ATPase activity^{61,62}. There have been reports of inhibitors, such as novobiocin, that bind to the CTD, potentially acting by interfering with allostery or dimerization⁶³.

Hsp90 Co-Chaperones.

Hsp90 interacts with a number of co-chaperones that tune its ATPase activity and control its association with clients (Figure 3)⁶⁴. The co-chaperone, Aha1, interacts tightly (K_d ~0.7

μM) through hydrophobic contacts with the first alpha-beta-alpha domain of the MD, as well as more widely distributed polar interactions and, by NMR, contact with the NTD⁶⁵. Binding of Aha1 causes a conformational change in the catalytic loop of Hsp90, displacing HOP and releasing Arg 380 to access the ATP binding site in the NTD⁶⁶. Another co-chaperone, p23, binds ($K_d \sim 1 \mu\text{M}$) as a dimer between the NTDs of two Hsp90s, inhibiting ATPase activity by stabilizing the ATP-bound, closed state⁴. Additional contacts are made between p23 and the inter-domain junction (where the MD of one protomer interacts with the NTD of the other protomer). Because this site is shared by Aha1, binding of p23 and Aha1 are mutually exclusive. Moreover, geldanamycin limits association of Hsp90 with p23⁶⁷, likely through an allosteric mechanism. Finally, the co-chaperone, Cdc37, interacts with both the NTD and MD⁶⁸. The major feature of Cdc37 is that it is required for maturation of kinases. Indeed, the structure of a kinase/Cdc37/Hsp90 complex reveals that this interaction occurs in the closed state of Hsp90, in which Cdc37 mimics interactions between p23 and the NTD while making additional, polar contacts with the MD. This interaction partially inhibits ATPase activity by limiting lid closure. Celastrol has been reported to disrupt the interaction of Cdc37 and Hsp90 by binding to the CTD⁶⁹, although its selectivity remains uncertain.

3. Small Heat Shock Proteins.

The small heat shock proteins (sHsps) are a class of ~ 10 non-enzymatic chaperones that bind partially unfolded client proteins to maintain their solubility⁷⁰. All sHsps contain a highly conserved α -crystallin domain (ACD) flanked by variable N- and C-termini (Figure 4A). A key feature is that these monomers assemble, using a series of PPIs described below, into large, polydisperse oligomers with sizes ranging from dimers to over 40 subunits⁷¹. Some studies suggest that smaller oligomers might be more potent chaperones, such that changes in oligomer size may be functionally important⁷². Thus, like other chaperone families, the biology of sHsps seems to be driven by dynamic PPIs, both with each other and with their clients.

Oligomeric Interactions of the sHsps.

The simplest unit of the sHsps is the dimer, which is driven by the interaction of two ACDs. Each ACD is a highly conserved β -sandwich and two of them come together into a compact structure via anti-parallel β -sheets. Although similar in overall architecture, the dimer interfaces amongst the human sHsps are not identical (Figure 4B). For example, the interface of αB crystallin's ACD dimer has many salt bridges that can act as a pH sensor⁷³, while that of Hsp27 contains a cysteine bridge that forms a redox sensor⁷⁴. These observations support the idea that chaperone function is linked to regulation of this PPI. In addition, the ACD interface is the one PPI in this system that has a known chemical probe; our group discovered a class of oxysterols that stabilize this contact, with the lead molecule, C29, making contacts with both sides of the anti-parallel β -sheet¹⁷. Because mutations of this interface can lead to hereditary cataracts, C29 stabilizes the folding of these proteins and it is currently in pre-clinical development as a non-surgical cataract treatment.

Other PPIs within sHsp oligomers are mediated by the highly variable and flexible C-terminal extensions (CTE). Specifically, some sHsps contain a conserved IXI (or IPV) motif within their CTEs. This motif binds to a groove formed by the $\beta 4/\beta 8$ strands on the edge of the ACD^{75,76}. Thus, within an oligomer, the IXI/V motif of one sHsp is proposed to “reach back” and take part in a PPI with the ACD of another sHsp (Figure 4C), stabilizing large oligomers.

The final PPI involves the N-terminal domain (NTD). Because the NTD is the least conserved region and is highly flexible, this PPI is difficult to study and remains the most enigmatic. NTDs within an oligomer seem to make contact with other NTDs (Figure 4D), though it is possible that they interact transiently with other domains as well, including the ACD (Figure 4E). Regardless, it is clear that the NTD PPIs are important for oligomer formation based on deletion studies⁷⁷. Moreover, the NTDs of different sHsps seem to encode different oligomeric sizes and polydispersity, as transposition of the NTD from Hsp27 onto MjHsp16.5 can change the MjHsp16.5 oligomer to become more “Hsp27-like”⁷⁸.

Hetero-oligomerization of sHsps.

The sHsps are known to form hetero-oligomers. This phenomenon has been extensively observed⁷⁹, most famously in lens α -crystallin hetero-oligomers that consists of αA and αB crystallin⁸⁰. The functions of hetero-oligomers are not always clear but their properties seem to be distinct from that of homo-oligomers⁸⁰. Hetero-oligomers are presumably held together by the same conserved PPIs, involving the IXI/V motifs and ACDs. However, the role of the NTD is less clear because it either promotes or disfavors hetero-oligomerization through unknown mechanisms⁸¹.

Client Interactions with sHsps.

How sHsps bind clients is not well understood, but an emerging model suggests that multiple domains are involved. Cross-linking studies in plant sHsps suggest that the NTD is the preferred client-binding site, with other regions involved in secondary interactions⁸². However, the ACD of αB crystallin, lacking an NTD, is sufficient to prevent aggregation of certain amyloid clients⁸³ and NMR studies indicate that the $\beta 4/\beta 8$ groove is an important binding site⁸⁴. Thus, interactions outside the NTD might be critical for some systems. That being said, deletion of the NTD is sufficient to ablate chaperone activity for lysozyme⁸⁴. For still other categories of clients, both the NTD and ACD have been shown to be important for chaperone activity⁸⁵. Taken together, these data suggest that client binding can occur in multiple sites, depending on the type of client and the sHsp oligomeric state.

Connections with Other Chaperones:

Because sHsps lack enzymatic activity, they must coordinate with other chaperone families to engage in complex functions. For example, sHsps are thought to create a reservoir of partially unfolded clients that are then refolded by the Hsp70/40 system⁸⁶ and Hsp100/ClpB system⁸⁷. In humans, BAG3 seems to be the scaffolding factor that connects the sHsps with Hsp70 via its BAG domain and IPV motifs⁸⁸. These PPIs are especially important in autophagy⁸⁹, where the BAG3/HspB8/Hsp70 complex has been shown to be required.

Conclusions.

Protein-protein interactions are the “glue” that holds together the chaperone network (see Fig 1). However, this glue is not static; rather, dynamic changes in PPIs seem to accompany the major “decisions” of proteostasis. The dynamic nature of the system is by design, enabling the chaperone network to rapidly adapt to a number of different stresses by altering the equilibria of PPIs. For example, sudden high concentrations of a client protein can favor chaperone binding to client while disfavoring particular co-chaperone-chaperone complexes. Because of the integration of the full chaperone network through PPIs, one change in a chaperone complex might reverberate through the entire network. While fascinating, this fluidity can make it challenging to study chaperone networks in a cellular context. In the next sections, we focus conclusions on the next-generation areas that we feel deserve further development.

Linking PPI Observations Across Scales.—Although we have focused primarily on structural examinations of individual PPIs in this Account, mass spectrometry has recently been used to globally profile PPIs within cells⁹⁰. This approach is yielding unprecedented insight into the broader interactions of chaperones, co-chaperones and clients. At the same time, advances in crystallography, NMR and cryo-EM have started to provide structures of larger and larger complexes, such as Hsp104-client⁹¹. These advances underscore the importance of understanding affinities of specific chaperone complexes *in vitro* and then bridging those observations across larger scales: from biochemical to cellular to organismal. Integration of this knowledge will require biophysics, mathematical modelling, biochemistry, functional genomics and other disciplines. In addition, it seems that chemical biology may play a particularly important role, because of its ability to produce molecules that operate at each scale.

Cellular Context.—While the core structure of the chaperone network seems to be maintained in different cell types and even cellular compartments, the specific cochaperones can vary significantly and the expression levels are varied. Recent work has identified a distinct chaperone complex (dubbed the epichaperome) present in many cancer cells that is absent in normal cells and other cancer lines⁹², suggesting that differences in the chaperone networks can contribute to disease. Furthermore, the makeup of the chaperone network might provide a therapeutic window for targeting specific cellular types, such as cancer cells.

Chemical Biology to Drug Discovery.—Together, converging revolutions in structural biology, proteomics and other fields are creating new opportunities for chemical biology, as each of the newly characterized PPIs is a potential, new site for perturbation. We suggest that drug-like molecules targeting these PPIs will continue to be invaluable tools for understanding chaperone networks, particularly because fast chemical perturbation of these highly dynamic interactions is critically important in understanding the overall network. Moreover, such molecules might be starting points for developing next-generation therapeutics. To this end, it will be important that HTS methods and medicinal chemistry campaigns retain drug-like criteria in the selection schemes, so that these important advances can be used to go beyond chemical probes and into clinical candidates. Recent

successes in targeting PPIs in the clinic should embolden this effort and inform the specific challenges ahead.

Biographical Information

Rebecca Freilich received her B.S. in Chemistry from New York University. Her graduate work involves protein-protein interactions of the small heat shock proteins.

Taylor Arhar earned a B.S. from Loyola Marymount University. Her thesis work focuses on characterizing interactions between co-chaperones and client proteins.

Jennifer L. Abrams earned a Ph.D. from the UT Health Sciences Center in Houston. She is using genetic screens to map chaperone-client interactions.

Jason E. Gestwicki received a Ph.D. from the University of Wisconsin, Madison and completed postdoctoral studies at Stanford University. He is currently a Professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco, where his group studies protein homeostasis in disease.

References:

- (1). Hartl FU ; Bracher A ; Hayer-Hartl M Molecular chaperones in protein folding and proteostasis. *Nature* 2011, 475, 324–332.21776078
- (2). Rauch JN ; Gestwicki JE Binding of human nucleotide exchange factors to heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro. *J Biol Chem* 2014, 289, 1402–1414.24318877
- (3). Assimon VA ; Southworth DR ; Gestwicki JE Specific Binding of Tetratricopeptide Repeat Proteins to Heat Shock Protein 70 (Hsp70) and Heat Shock Protein 90 (Hsp90) Is Regulated by Affinity and Phosphorylation. *Biochemistry* 2015, 54, 7120–7131.26565746
- (4). Ali MM ; Roe SM ; Vaughan CK ; Meyer P ; Panaretou B ; Piper PW ; Prodromou C ; Pearl LH Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. *Nature* 2006, 440, 1013–1017.16625188
- (5). Wisen S ; Bertelsen EB ; Thompson AD ; Patury S ; Ung P ; Chang L ; Evans CG ; Walter GM ; Wipf P ; Carlson HA ; Brodsky JL ; Zuiderweg ER ; Gestwicki JE Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40. *ACS chemical biology* 2010, 5, 611–622.20481474
- (6). Briknarova K ; Takayama S ; Brive L ; Havert ML ; Knee DA ; Velasco J ; Homma S ; Cabezas E ; Stuart J ; Hoyt DW ; Satterthwait AC ; Llinas M ; Reed JC ; Ely KR Structural analysis of BAG1 cochaperone and its interactions with Hsc70 heat shock protein. *Nat Struct Biol* 2001, 8, 349–352.11276257
- (7). Assimon VA ; Gillies AT ; Rauch JN ; Gestwicki JE Hsp70 protein complexes as drug targets. *Curr Pharm Des* 2013, 19, 404–417.22920901
- (8). Pratt WB ; Toft DO Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. *Exp Biol Med (Maywood)* 2003, 228, 111–133.12563018
- (9). Cho Y ; Zhang X ; Pobre KF ; Liu Y ; Powers DL ; Kelly JW ; Gierasch LM ; Powers ET Individual and collective contributions of chaperoning and degradation to protein homeostasis in *E. coli*. *Cell reports* 2015, 11, 321–333.25843722
- (10). Kundrat L ; Regan L Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP. *Biochemistry* 2010, 49, 7428–7438.20704274
- (11). Powers ET ; Powers DL ; Gierasch LM FoldEco: a model for proteostasis in *E. coli*. *Cell reports* 2012, 1, 265–276.22509487

- (12). Cesa LC ; Mapp AK ; Gestwicki JE Direct and Propagated Effects of Small Molecules on Protein-Protein Interaction Networks. *Frontiers in bioengineering and biotechnology* 2015, 3, 119.26380257
- (13). Ouimet CM ; Dawod M ; Grinias J ; Assimon VA ; Lodge J ; Mapp AK ; Gestwicki JE ; Kennedy RT Protein cross-linking capillary electrophoresis at increased throughput for a range of protein-protein interactions. *Analyst* 2018, DOI:10.1039/C7AN02098H10.1039/C7AN02098H.
- (14). Rauch JN ; Nie J ; Buchholz TJ ; Gestwicki JE ; Kennedy RT Development of a capillary electrophoresis platform for identifying inhibitors of protein-protein interactions. *Anal Chem* 2013, 85, 9824–9831.24060167
- (15). Taylor IR ; Dunyak BM ; Komiyama T ; Shao H ; Ran X ; Assimon VA ; Kalyanaraman C ; Rauch JN ; Jacobson MP ; Zuiderweg ERP ; Gestwicki JE High Throughput Screen for Inhibitors of Protein-Protein Interactions in a Reconstituted Heat Shock Protein 70 (Hsp70) Complex. *J Biol Chem* 2018, DOI:10.1074/jbc.RA117.00157510.1074/jbc.RA117.001575.
- (16). Cesa LC ; Patury S ; Komiyama T ; Ahmad A ; Zuiderweg ER ; Gestwicki JE Inhibitors of difficult protein-protein interactions identified by high-throughput screening of multiprotein complexes. *ACS Chem Biol* 2013, 8, 1988–1997.23819499
- (17). Makley LN ; McMenimen KA ; DeVree BT ; Goldman JW ; McGlasson BN ; Rajagopal P ; Dunyak BM ; McQuade TJ ; Thompson AD ; Sunahara R ; Klevit RE ; Andley UP ; Gestwicki JE Pharmacological chaperone for alpha-crystallin partially restores transparency in cataract models. *Science* 2015, 350, 674–677.26542570
- (18). Roth DM ; Hutt DM ; Tong J ; Bouche-careilh M ; Wang N ; Seeley T ; Dekkers JF ; Beekman JM ; Garza D ; Drew L ; Masliah E ; Morimoto RI ; Balch WE Modulation of the maladaptive stress response to manage diseases of protein folding. *PLoS Biol* 2014, 12, e1001998.25406061
- (19). Balch WE ; Morimoto RI ; Dillin A ; Kelly JW Adapting proteostasis for disease intervention. *Science* 2008, 319, 916–919.18276881
- (20). Clerico EM ; Tilitsky JM ; Meng W ; Gierasch LM How hsp70 molecular machines interact with their substrates to mediate diverse physiological functions. *J Mol Biol* 2015, 427, 1575–1588.25683596
- (21). Zuiderweg ER ; Hightower LE ; Gestwicki JE The remarkable multivalency of the Hsp70 chaperones. *Cell Stress Chaperones* 2017, 22, 173–189.28220454
- (22). Bocking T ; Aguet F ; Harrison SC ; Kirchhausen T Single-molecule analysis of a molecular disassemblase reveals the mechanism of Hsc70-driven clathrin uncoating. *Nat Struct Mol Biol* 2011, 18, 295–301.21278753
- (23). Kampinga HH ; Craig EA The HSP70 chaperone machinery: J proteins as drivers of functional specificity. *Nat Rev Mol Cell Biol* 2010, 11, 579–592.20651708
- (24). Ahmad A ; Bhattacharya A ; McDonald RA ; Cordes M ; Ellington B ; Bertelsen EB ; Zuiderweg ER Heat shock protein 70 kDa chaperone/DnaJ cochaperone complex employs an unusual dynamic interface. *Proceedings of the National Academy of Sciences of the United States of America* 2011, 108, 18966–18971.22065753
- (25). Greene MK ; Maskos K ; Landry SJ Role of the J-domain in the cooperation of Hsp40 with Hsp70. *Proc Natl Acad Sci U S A* 1998, 95, 6108–6113.9600925
- (26). Kityk R ; Kopp J ; Mayer MP Molecular Mechanism of J-Domain-Triggered ATP Hydrolysis by Hsp70 Chaperones. *Mol Cell* 2018, 69, 227–237 e224.29290615
- (27). Huryn DM ; Brodsky JL ; Brummond KM ; Chambers PG ; Eyer B ; Ireland AW ; Kawasumi M ; Laporte MG ; Lloyd K ; Manteau B ; Nghiem P ; Quade B ; Seguin SP ; Wipf P Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators. *Proc Natl Acad Sci U S A* 2011, 108, 6757–6762.21502524
- (28). Chafekar SM ; Wisen S ; Thompson AD ; Echeverria A ; Walter GM ; Evans CG ; Makley LN ; Gestwicki JE ; Duennwald ML Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation. *ACS chemical biology* 2012, 7, 1556–1564.22709427
29.) Schilke BA ; Ciesielski SJ ; Ziegelhoffer T ; Kamiya E ; Tonelli M ; Lee W ; Cornilescu G ; Hines JK ; Markley JL ; Craig EA Broadening the functionality of a J-protein/Hsp70 molecular chaperone system. *PLoS genetics* 2017, 13, e1007084.29084221

- (30). Nillegoda NB ; Kirstein J ; Szlachet A ; Berynskyy M ; Stank A ; Stengel F ; Arnsburg K ; Gao X ; Scior A ; Aebersold R ; Guilbride DL ; Wade RC ; Morimoto RI ; Mayer MP ; Bukau B Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. *Nature* 2015, 524, 247–251.26245380
- (31). Bracher A ; Verghese J The nucleotide exchange factors of Hsp70 molecular chaperones. *Frontiers in molecular biosciences* 2015, 2, 10.26913285
- (32). Harrison CJ ; Hayer-Hartl M ; Di Liberto M ; Hartl F ; Kuriyan J Crystal structure of the nucleotide exchange factor GrpE bound to the ATPase domain of the molecular chaperone DnaK. *Science* 1997, 276, 431–435.9103205
- (33). Sondermann H ; Scheufler C ; Schneider C ; Hohfeld J ; Hartl FU ; Moarefi I Structure of a Bag/Hsc70 complex: convergent functional evolution of Hsp70 nucleotide exchange factors. *Science* 2001, 291, 1553–1557.11222862
- (34). Rosam M ; Krader D ; Nickels C ; Hochmair J ; Back KC ; Agam G ; Barth A ; Zeymer C ; Hendrix J ; Schneider M ; Antes I ; Reinstein J ; Lamb DC ; Buchner J Bap (Sil1) regulates the molecular chaperone BiP by coupling release of nucleotide and substrate. *Nat Struct Mol Biol* 2018, 25, 90–100.29323281
- (35). Gowda NKC ; Kaimal JM ; Kityk R ; Daniel C ; Liebau J ; Ohman M ; Mayer MP ; Andreasson C Nucleotide exchange factors Fes1 and HspBP1 mimic substrate to release misfolded proteins from Hsp70. *Nat Struct Mol Biol* 2018, 25, 83–89.29323280
- (36). Polier S ; Dragovic Z ; Hartl FU ; Bracher A Structural basis for the cooperation of Hsp70 and Hsp110 chaperones in protein folding. *Cell* 2008, 133, 1068–1079.18555782
- (37). Shomura Y ; Dragovic Z ; Chang HC ; Tzvetkov N ; Young JC ; Brodsky JL ; Guerriero V ; Hartl FU ; Bracher A Regulation of Hsp70 function by HspBP1: structural analysis reveals an alternate mechanism for Hsp70 nucleotide exchange. *Mol Cell* 2005, 17, 367–379.15694338
- (38). Rousaki A ; Miyata Y ; Jinwal UK ; Dickey CA ; Gestwicki JE ; Zuiderweg ER Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones. *J Mol Biol* 2011, 411, 614–632.21708173
- (39). Young ZT ; Rauch JN ; Assimon VA ; Jinwal UK ; Ahn M ; Li X ; Dunyak BM ; Ahmad A ; Carlson GA ; Srinivasan SR ; Zuiderweg ER ; Dickey CA ; Gestwicki JE Stabilizing the Hsp70-Tau Complex Promotes Turnover in Models of Tauopathy. *Cell chemical biology* 2016, 23, 992–1001.27499529
- (40). Xu X ; Sarbeng EB ; Vorvis C ; Kumar DP ; Zhou L ; Liu Q Unique peptide substrate binding properties of 110-kDa heat-shock protein (Hsp110) determine its distinct chaperone activity. *J Biol Chem* 2012, 287, 5661–5672.22157767
- (41). Zeytuni N ; Zarivach R Structural and functional discussion of the tetra-trico-peptide repeat, a protein interaction module. *Structure* 2012, 20, 397–405.22404999
- (42). D'Andrea LD ; Regan L TPR proteins: the versatile helix. *Trends Biochem Sci* 2003, 28, 655–662.14659697
- (43). Scheufler C ; Brinker A ; Bourenkov G ; Pegoraro S ; Moroder L ; Bartunik H ; Hartl FU ; Moarefi I Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. *Cell* 2000, 101, 199–210.10786835
- (44). Smith MC ; Scaglione KM ; Assimon VA ; Patury S ; Thompson AD ; Dickey CA ; Southworth DR ; Paulson HL ; Gestwicki JE ; Zuiderweg ER The E3 Ubiquitin Ligase CHIP and the Molecular Chaperone Hsc70 Form a Dynamic, Tethered Complex. *Biochemistry* 2013, 52, 5354–5364.23865999
- (45). Hohfeld J ; Cyr DM ; Patterson C From the cradle to the grave: molecular chaperones that may choose between folding and degradation. *EMBO Rep* 2001, 2, 885–890.11600451
- (46). Evans CG ; Chang L ; Gestwicki JE Heat shock protein 70 (hsp70) as an emerging drug target. *J Med Chem* 2010, 53, 4585–4602.20334364
- (47). Li X ; Shao H ; Taylor IR ; Gestwicki JE Targeting Allosteric Control Mechanisms in Heat Shock Protein 70 (Hsp70). *Curr Top Med Chem* 2016, 16, 2729–2740.27072701
- (48). Abisambra J ; Jinwal UK ; Miyata Y ; Rogers J ; Blair L ; Li X ; Seguin SP ; Wang L ; Jin Y ; Bacon J ; Brady S ; Cockman M ; Guidi C ; Zhang J ; Koren J ; Young ZT ; Atkins CA ; Zhang B ; Lawson LY ; Weeber EJ ; Brodsky JL ; Gestwicki JE ; Dickey CA Allosteric heat shock

protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. *Biol Psychiatry* 2013, 74, 367–374.23607970

- (49). Wang AM ; Miyata Y ; Klinedinst S ; Peng HM ; Chua JP ; Komiyama T ; Li X ; Morishima Y ; Merry DE ; Pratt WB ; Osawa Y ; Collins CA ; Gestwicki JE ; Lieberman AP Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. *Nature chemical biology* 2013, 9, 112–118.23222885
- (50). Taguwa S ; Maringer K ; Li X ; Bernal-Rubio D ; Rauch JN ; Gestwicki JE ; Andino R ; Fernandez-Sesma A ; Frydman J Defining Hsp70 Subnetworks in Dengue Virus Replication Reveals Key Vulnerability in Flavivirus Infection. *Cell* 2015, 163, 1108–1123.26582131
- (51). Colvin TA ; Gabai VL ; Gong J ; Calderwood SK ; Li H ; Gummuluru S ; Matchuk ON ; Smirnova SG ; Orlova NV ; Zamulaeva IA ; Garcia-Marcos M ; Li X ; Young ZT ; Rauch JN ; Gestwicki JE ; Takayama S ; Sherman MY Hsp70-Bag3 interactions regulate cancer-related signaling networks. *Cancer Res* 2014, 74, 4731–4740.24994713
- (52). Pratt WB ; Gestwicki JE ; Osawa Y ; Lieberman AP Targeting hsp90/hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. *Annual review of pharmacology and toxicology* 2015, 55, 353–371.
- (53). Seyffer F ; Kummer E ; Oguchi Y ; Winkler J ; Kumar M ; Zahn R ; Sourjik V ; Bukau B ; Mogk A Hsp70 proteins bind Hsp100 regulatory M domains to activate AAA+ disaggregase at aggregate surfaces. *Nat Struct Mol Biol* 2012, 19, 1347–1355.23160352
- (54). Nakamoto H ; Fujita K ; Ohtaki A ; Watanabe S ; Narumi S ; Maruyama T ; Suenaga E ; Misono TS ; Kumar PK ; Goloubinoff P ; Yoshikawa H Physical interaction between bacterial heat shock protein (Hsp) 90 and Hsp70 chaperones mediates their cooperative action to refold denatured proteins. *J Biol Chem* 2014, 289, 6110–6119.24415765
- (55). Lee J ; Kim JH ; Biter AB ; Sielaff B ; Lee S ; Tsai FT Heat shock protein (Hsp) 70 is an activator of the Hsp104 motor. *Proc Natl Acad Sci U S A* 2013, 110, 8513–8518.23650362
- (56). Whitesell L ; Lindquist SL HSP90 and the chaperoning of cancer. *Nature reviews* 2005, 5, 761–772.
- (57). da Silva VC ; Ramos CH The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. *Journal of proteomics* 2012, 75, 2790–2802.22236519
- (58). Prodromou C ; Roe SM ; O'Brien R ; Ladbury JE ; Piper PW ; Pearl LH Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. *Cell* 1997, 90, 65–75.9230303
- (59). Meyer P ; Prodromou C ; Hu B ; Vaughan C ; Roe SM ; Panaretou B ; Piper PW ; Pearl LH Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. *Mol Cell* 2003, 11, 647–658.12667448
- (60). Nemoto T ; Ohara-Nemoto Y ; Ota M ; Takagi T ; Yokoyama K Mechanism of dimer formation of the 90-kDa heat-shock protein. *Eur J Biochem* 1995, 233, 1–8.7588731
- (61). Workman P ; Burrows F ; Neckers L ; Rosen N Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. *Ann N Y Acad Sci* 2007, 1113, 202–216.17513464
- (62). Shrestha L ; Patel HJ ; Chiosis G Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease. *Cell chemical biology* 2016, 23, 158–172.26933742
- (63). Garg G ; Khandelwal A ; Blagg BS Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects. *Adv Cancer Res* 2016, 129, 51–88.26916001
- (64). Li J ; Soroka J ; Buchner J The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. *Biochim Biophys Acta* 2012, 1823, 624–635.21951723
- (65). Retzlaff M ; Hagn F ; Mitschke L ; Hessling M ; Gugel F ; Kessler H ; Richter K ; Buchner J Asymmetric activation of the hsp90 dimer by its cochaperone aha1. *Mol Cell* 2010, 37, 344–354.20159554
- (66). Meyer P ; Prodromou C ; Liao C ; Hu B ; Mark Roe S ; Vaughan CK ; Vlasic I ; Panaretou B ; Piper PW ; Pearl LH Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. *EMBO J* 2004, 23, 511–519.14739935

- (67). Sullivan W ; Stensgard B ; Caucutt G ; Bartha B ; McMahon N ; Alnemri ES ; Litwack G ; Toft D Nucleotides and two functional states of hsp90. *J Biol Chem* 1997, 272, 8007–8012.9065472
- (68). Verba KA ; Wang RY ; Arakawa A ; Liu Y ; Shirouzu M ; Yokoyama S ; Agard DA Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. *Science* 2016, 352, 1542–1547.27339980
- (69). Zhang T ; Hamza A ; Cao X ; Wang B ; Yu S ; Zhan CG ; Sun D A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. *Mol Cancer Ther* 2008, 7, 162–170.18202019
- (70). Haslbeck M ; Vierling E A first line of stress defense: small heat shock proteins and their function in protein homeostasis. *J Mol Biol* 2015, 427, 1537–1548.25681016
- (71). Delbecq SP ; Klevit RE One size does not fit all: the oligomeric states of alphaB crystallin. *FEBS Lett* 2013, 587, 1073–1080.23340341
- (72). Giese KC ; Vierling E Changes in oligomerization are essential for the chaperone activity of a small heat shock protein in vivo and in vitro. *J Biol Chem* 2002, 277, 46310–46318.12297515
- (73). Rajagopal P ; Tse E ; Borst AJ ; Delbecq SP ; Shi L ; Southworth DR ; Klevit RE A conserved histidine modulates HSPB5 structure to trigger chaperone activity in response to stress-related acidosis. *eLife* 2015, 4.
- (74). Rajagopal P ; Liu Y ; Shi L ; Clouser AF ; Klevit RE Structure of the alpha-crystallin domain from the redox-sensitive chaperone, HSPB1. *J Biomol NMR* 2015, 63, 223–228.26243512
- (75). Jehle S ; van Rossum B ; Stout JR ; Noguchi SM ; Falber K ; Rehbein K ; Oschkinat H ; Klevit RE ; Rajagopal P alphaB-crystallin: a hybrid solid-state/solution-state NMR investigation reveals structural aspects of the heterogeneous oligomer. *J Mol Biol* 2009, 385, 1481–1497.19041879
- (76). Delbecq SP ; Jehle S ; Klevit R Binding determinants of the small heat shock protein, alphaB-crystallin: recognition of the 'IxI' motif. *EMBO J* 2012, 31, 4587–4594.23188086
- (77). Peschek J ; Braun N ; Rohrborg J ; Back KC ; Kriehuber T ; Kastenmuller A ; Weinkauff S ; Buchner J Regulated structural transitions unleash the chaperone activity of alphaB-crystallin. *Proc Natl Acad Sci U S A* 2013, 110, E3780–3789.24043785
- (78). Shi J ; Koteiche HA ; McHaourab HS ; Stewart PL Cryoelectron microscopy and EPR analysis of engineered symmetric and polydisperse Hsp16.5 assemblies reveals determinants of polydispersity and substrate binding. *J Biol Chem* 2006, 281, 40420–40428.17079234
- (79). Arrigo AP Human small heat shock proteins: protein interactomes of homo- and hetero-oligomeric complexes: an update. *FEBS Lett* 2013, 587, 1959–1969.23684648
- (80). Srinivas PN ; Reddy PY ; Reddy GB Significance of alpha-crystallin heteropolymer with a 3:1 alphaA/alphaB ratio: chaperone-like activity, structure and hydrophobicity. *Biochem J* 2008, 414, 453–460.18479247
- (81). Heirbaut M ; Lermyte F ; Martin EM ; Beelen S ; Verschueren T ; Sobott F ; Strelkov SV ; Weeks SD The preferential heterodimerization of human small heat shock proteins HSPB1 and HSPB6 is dictated by the N-terminal domain. *Arch Biochem Biophys* 2016, 610, 41–50.27717639
- (82). Jaya N ; Garcia V ; Vierling E Substrate binding site flexibility of the small heat shock protein molecular chaperones. *Proc Natl Acad Sci U S A* 2009, 106, 15604–15609.19717454
- (83). Hochberg GK ; Ecroyd H ; Liu C ; Cox D ; Cascio D ; Sawaya MR ; Collier MP ; Stroud J ; Carver JA ; Baldwin AJ ; Robinson CV ; Eisenberg DS ; Benesch JL ; Laganowsky A The structured core domain of alphaB-crystallin can prevent amyloid fibrillation and associated toxicity. *Proc Natl Acad Sci U S A* 2014, 111, E1562–1570.24711386
- (84). Mainz A ; Peschek J ; Stavropoulou M ; Back KC ; Bardiaux B ; Asami S ; Prade E ; Peters C ; Weinkauff S ; Buchner J ; Reif B The chaperone alphaB-crystallin uses different interfaces to capture an amorphous and an amyloid client. *Nat Struct Mol Biol* 2015, 22, 898–905.26458046
- (85). Basha E ; Friedrich KL ; Vierling E The N-terminal arm of small heat shock proteins is important for both chaperone activity and substrate specificity. *J Biol Chem* 2006, 281, 39943–39952.17090542
- (86). Lee GJ ; Vierling E A small heat shock protein cooperates with heat shock protein 70 systems to reactivate a heat-denatured protein. *Plant Physiol* 2000, 122, 189–198.10631262

- (87). Haslbeck M ; Miess A ; Stromer T ; Walter S ; Buchner J Disassembling protein aggregates in the yeast cytosol. The cooperation of Hsp26 with Ssa1 and Hsp104. *J Biol Chem* 2005, 280, 23861–23868.15843375
- (88). Rauch JN ; Tse E ; Freilich R ; Mok SA ; Makley LN ; Southworth DR ; Gestwicki JE BAG3 Is a Modular, Scaffolding Protein that physically Links Heat Shock Protein 70 (Hsp70) to the Small Heat Shock Proteins. *J Mol Biol* 2017, 429, 128–141.27884606
- (89). Carra S ; Seguin SJ ; Landry J HspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagy. *Autophagy* 2008, 4, 237–239.18094623
- (90). Rizzolo K ; Huen J ; Kumar A ; Phanse S ; Vlasblom J ; Kakihara Y ; Zeineddine HA ; Minic Z ; Snider J ; Wang W ; Pons C ; Seraphim TV ; Boczek EE ; Alberti S ; Costanzo M ; Myers CL ; Stagljar I ; Boone C ; Babu M ; Houry WA Features of the Chaperone Cellular Network Revealed through Systematic Interaction Mapping. *Cell reports* 2017, 20, 2735–2748.28903051
- (91). Gates SN ; Yokom AL ; Lin J ; Jackrel ME ; Rizo AN ; Kendersky NM ; Buell CE ; Sweeny EA ; Mack KL ; Chuang E ; Torrente MP ; Su M ; Shorter J ; Southworth DR Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104. *Science* 2017, 357, 273–279.28619716
- (92). Rodina A ; Wang T ; Yan P ; Gomes ED ; Dunphy MP ; Pillarsetty N ; Koren J ; Gerecitano JF ; Taldone T ; Zong H ; Caldas-Lopes E ; Alpaugh M ; Corben A ; Riolo M ; Beattie B ; Pressl C ; Peter RI ; Xu C ; Trondl R ; Patel HJ ; Shimizu F ; Bolaender A ; Yang C ; Panchal P ; Farooq MF ; Kishinevsky S ; Modi S ; Lin O ; Chu F ; Patil S ; Erdjument-Bromage H ; Zanzonico P ; Hudis C ; Studer L ; Roboz GJ ; Cesarman E ; Cerchietti L ; Levine R ; Melnick A ; Larson SM ; Lewis JS ; Guzman ML ; Chiosis G The epichaperome is an integrated chaperome network that facilitates tumour survival. *Nature* 2016, 538, 397–401.27706135

Figure 1. The physical interactions of the major chaperone families.

PPIs are shown with red lines and the approximate surfaces indicated on the cartoons.

Dotted lines indicated interactions that lack a high-resolution structure.

A. Hsp70 interacts with major categories of co-chaperones through a series of PPIs

B. Reported structures of Hsp70 PPIs with co-chaperones

PDB ID [ref]	Organism	Co-chaperone type	Co-chaperone	Regions of Hsp70 contact
2QWN	Bovine	J protein	Auxilin	NBD, lobes IA and IIA
5NRO	E. Coli	J protein	DnaJ	NBD lobe IIA, interdomain linker, SBD β
3D2F	Human	NEF	Sse1 (Hsp110)	NBD, lobes IA, IB, and IIB
1DKG	E. Coli	NEF	GrpE	NBD, lobes IA, IB, and IIB
1HX1	Human	NEF	Bag1	NBD, lobes IB and IIB
3CQX	Human	NEF	Bag2	NBD, lobes IB and IIB
38AY	Human	NEF	Bag5	NBD, lobes IB and IIB
1XQS	Human	NEF	HspBP1	NBD, lobe IIB
1ELW	Human	TPR	HOP	EEVD
4KBQ	Human	TPR	CHIP	EEVD
4J8F	Human	TPR	HIP	NBD, lobes IA, IB, and IIB

Figure 2. Hsp70's interaction with co-chaperones.

A, Categories of co-chaperone PPIs in the Hsp70 sub-network, highlighting the different regions of Hsp70 that are involved. B. Structures of Hsp70 complexes.

Figure 3. PPIs with Hsp90.

A) The interaction between Aha1 and Hsp90 is modeled by alignment of the co-crystal structure of the N-terminal domain of Aha1 and Hsp90 MD with the structure of full-length Hsp90 in the closed state (PDB 2CG9). The C-terminal domain of Aha1 (not shown) has been reported to interact with the Hsp90 NTD. B) Two p23 molecules bind to the Hsp90 dimer, each binding between the Hsp90 NTDs. C) Cdc37 wraps around Hsp90, splitting into two domains connected by a beta strand that packs against the Hsp90 MD.

Figure 4. PPIs of the sHsps.

A, Domain architecture of sHsps. B, Examples of dimer interfaces: α B crystallin (PDB: 2WJ7) and MjHSP16 (PDB: 1SHS). Key contacts are shown (red arrows). C, Structure of an IPV peptide bound to Hsp27 β 4/ β 8 groove (PDB: 4MJH). D, Potential NTD contacts based on EM models. E, Models of α B crystallin oligomers from electron microscopy.